Evidence map›Paper›PMID 27841290›Full record

ArticleScientific reports2016

Downregulation of oncogenic RAS and c-Myc expression in MOLT-4 leukaemia cells by a salicylaldehyde semicarbazone copper(II) complex.

Yan-Yih Goh, Yaw-Kai Yan, Nguan Soon Tan, Su-Ann Goh, Shang Li, You-Chuan Teoh, Peter P F Lee

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yan-Yih GohNatural Sciences &Science Education, National Institute of Education, Nanyang Technological University, 1 Nanyang Walk, Singapore 637616, Singapore.
Yaw-Kai YanNatural Sciences &Science Education, National Institute of Education, Nanyang Technological University, 1 Nanyang Walk, Singapore 637616, Singapore.
Nguan Soon TanSchool of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551.
Su-Ann GohDuke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
Shang LiDuke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
You-Chuan TeohNatural Sciences &Science Education, National Institute of Education, Nanyang Technological University, 1 Nanyang Walk, Singapore 637616, Singapore.
Peter P F LeeSingapore Institute of Technology, 10 Dover Drive, Singapore 138683, Singapore.
Nanyang Technological University · SGDuke-NUS Medical School · SGSingapore Institute of Technology · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copper complexes with potent anti-tumor effect have been extensively developed. Most investigations of their modes of action focused on the biomolecular targets but not the signal transduction between target binding and cell death. We have previously shown that the cytotoxic complex pyridine(2,4-dihydroxybenzaldehyde dibenzyl semicarbazone)copper(II) (complex 1) shows selective binding to human telomeric G-quadruplex DNA over double-stranded DNA in vitro. Herein, we elucidate the mechanism of action by which complex 1 induces apoptosis in MOLT-4 cells. Complex 1 accumulates in the nuclei and differentially downregulates the expression of c-Myc, c-Kit and KRAS oncogenes. Chemical affinity capture assay results show that the complex is associated with c-Myc and KRAS quadruplex sequences in MOLT-4 cells. We further showed that the reduction in Ras protein expression resulted in attenuated MEK-ERK and PI3K-Akt signalling activities, leading to the activation of caspase-dependent apoptosis. Notably, complex 1 increased the sensitivity of MOLT-4 cells to cisplatin and vice versa. Overall, we demonstrated that complex 1 induces apoptosis, at least in part, by suppressing KRAS, c-Kit and c-Myc oncogene expression and the pro-survival MEK-ERK and PI3K-Akt signalling pathways.

Indexed as

Down-RegulationApoptosisCell Line, TumorCisplatinDrug SynergismGene Expression Regulation, NeoplasticHumansLeukemiaMAP Kinase Signaling SystemOrganometallic CompoundsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)SemicarbazonesCisplatinKRAS protein, humanMYC protein, humanOrganometallic CompoundsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)Semicarbazones

Identifiers

PMID27841290
PMCPMC5107956
OpenAlexW2553771009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.